GlassScriptPhysician profile
John Weston Evans
NPI 1912433244
$3,981.60
in general payments reported to CMS, 2019-2025
26 companies · $734 in 2025
The $734 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $862 · 2023: $1,558 · 2024: $700 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Education: $26.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.38 |
| Education | $26.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.43 | 2021-2025 | |
| Novo Nordisk INC | $521.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $479.19 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $414.85 | 2021-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $352.67 | 2022-2025 | Trintellix |
| Amgen INC. | $329.44 | 2021-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $291.51 | 2022-2024 | |
| Pfizer INC. | $216.05 | 2023-2025 | |
| Abbott Laboratories | $101.69 | 2023-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $94.51 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $93.31 | 2021-2023 | Ajovy |
| Astellas Pharma US INC | $85.56 | 2023-2025 | Veozah |
| Corcept Therapeutics | $59.13 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $58.43 | 2023-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $58.32 | 2023-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $34.53 | 2023 | Seglentis |
| Phathom Pharmaceuticals, INC. | $26.32 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $22.73 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $22.58 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.29 | 2023 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.97 | 2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $19.81 | 2022 | |
| Insulet Corporation | $17.15 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $14.10 | 2022 | |
| Esperion Therapeutics, INC. | $13.93 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.